We are live on ! Find out more
Baillie Gifford & Co

Baillie Gifford & Co Portfolio holdings

AUM $110B
1-Year Est. Return 4.8%
 

Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.

This Fund
S&P 500
This Quarter Est. Return
+34.19%
1 Year Est. Return
+4.8%
3 Year Est. Return
+123.53%
5 Year Est. Return
+125.55%
10 Year Est. Return
+1,754.37%
AUM
$180B
AUM Growth
+$34.5B
Cap. Flow
+$124M
Cap. Flow %
0.07%
Top 10 Hldgs %
43.41%
Holding
443
New
192
Increased
135
Reduced
77
Closed
14

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$1.73B
2
ONC
BeOne Medicines Ltd
ONC
+$774M
3
ILMN icon
Illumina
ILMN
+$691M
4
DXCM icon
DexCom
DXCM
+$438M
5
NFLX icon
Netflix
NFLX
+$360M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 37.71%
2 Technology 16.18%
3 Healthcare 15.43%
4 Communication Services 14.41%
5 Financials 5.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EPAM icon
276
EPAM Systems
EPAM
$5.03B
$41K ﹤0.01%
+115
New +$38.4K
HALO icon
277
Halozyme
HALO
$12.2B
$41K ﹤0.01%
+954
New +$34.3K
GBT
278
DELISTED
Global Blood Therapeutics, Inc.
GBT
$41K ﹤0.01%
+950
New +$46.8K
BEAM icon
279
Beam Therapeutics
BEAM
$2.84B
$40K ﹤0.01%
+495
New +$24.3K
AYX
280
DELISTED
Alteryx Inc
AYX
$39K ﹤0.01%
+321
New +$40.5K
SPWR
281
DELISTED
SunPower Corporation Common Stock
SPWR
$38K ﹤0.01%
+1,486
New +$30.1K
INSP icon
282
Inspire Medical Systems
INSP
$1.74B
$37K ﹤0.01%
+196
New +$32K
BMY icon
283
Bristol-Myers Squibb
BMY
$132B
$36K ﹤0.01%
+583
New +$35.8K
EBS icon
284
Emergent Biosolutions
EBS
$248M
$36K ﹤0.01%
+407
New +$37.4K
SRNE
285
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$35K ﹤0.01%
+5,109
New +$41K
POOL icon
286
Pool Corp
POOL
$7.5B
$34K ﹤0.01%
+90
New +$31.4K
VRNS icon
287
Varonis Systems
VRNS
$5B
$34K ﹤0.01%
+615
New +$26.7K
MXL icon
288
MaxLinear
MXL
$6.8B
$33K ﹤0.01%
+861
New +$25K
SNPS icon
289
Synopsys
SNPS
$79.7B
$33K ﹤0.01%
+128
New +$29.5K
P
290
Everpure Inc
P
$29.9B
$32K ﹤0.01%
+1,433
New +$27.5K
ZNGA
291
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
$32K ﹤0.01%
+3,281
New +$29.5K
CHRS icon
292
Coherus Oncology
CHRS
$196M
$30K ﹤0.01%
+1,703
New +$30.3K
SRPT icon
293
Sarepta Therapeutics
SRPT
$1.77B
$30K ﹤0.01%
+178
New +$26.4K
INFN
294
DELISTED
Infinera Corporation Common Stock
INFN
$30K ﹤0.01%
+2,842
New +$22.5K
MPWR icon
295
Monolithic Power Systems
MPWR
$68.9B
$29K ﹤0.01%
+79
New +$25.3K
REGN icon
296
Regeneron Pharmaceuticals
REGN
$80.8B
$29K ﹤0.01%
+60
New +$32.4K
ACAD icon
297
Acadia Pharmaceuticals
ACAD
$5.03B
$28K ﹤0.01%
+532
New +$26.4K
ANET icon
298
Arista Networks
ANET
$238B
$28K ﹤0.01%
+1,568
New +$24.8K
CRWD icon
299
CrowdStrike
CRWD
$218B
$28K ﹤0.01%
+528
New +$20.6K
PINS icon
300
Pinterest
PINS
$13.4B
$28K ﹤0.01%
+424
New +$25.4K

Similar funds

Baillie Gifford & Co's Q4 2020 Portfolio in Review

As of Q4 2020, Baillie Gifford & Co held 443 positions worth $180B, up 24% from $145B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Baillie Gifford & Co's Q4 2020 filing shows 192 new, 135 increased, 77 reduced and 14 closed positions. Its largest new stake was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M. The largest sale was Tesla, an estimated $3.79B.

By sector, the portfolio is most concentrated in Consumer Discretionary at 38% of assets, up from 37% a quarter earlier, followed by Technology and Healthcare.

  • Baillie Gifford & Co's largest Q4 2020 buy was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M.
  • Baillie Gifford & Co added most to Moderna in Q4 2020, an estimated $1.73B increase.
  • Baillie Gifford & Co's biggest Q4 2020 reduction was Tesla, cutting an estimated $3.79B.
  • Baillie Gifford & Co fully exited TD Ameritrade Holding Corp in Q4 2020, selling an estimated $264M.
  • Baillie Gifford & Co's ten largest holdings make up 43% of its $180B portfolio in Q4 2020.
  • Baillie Gifford & Co opened 192 new positions and closed 14 in Q4 2020.
  • Baillie Gifford & Co's portfolio value rose 24% quarter-over-quarter to $180B.

Based on Baillie Gifford & Co's 13F filing for Q4 2020, filed 10 Feb 2021.